Isracann Biosciences Inc announced that it will issue 50,000,000 units at CAD 0.06 per unit for gross proceeds of CAD 3,000,000 on April 15, 2022. The units consists of one common share and one share purchase warrant. Each warrant will entitle the holder to purchase one additional common share in the capital of the Company at a price of CAD 0.085 per warrant for a period of 48 months from the closing of the Offering.

The company may pay a commission to eligible finders in the transaction subjected to Canadian Securities Exchange. The closing is subject to a number of conditions, including receipt of all necessary corporate and regulatory approvals, including the TSX Venture Exchange. All securities issued in connection will be subject to a statutory hold period of four months plus a day from the date of issuance.